DOW JONES28,956.54-263.44 -0.90%
S&P 5003,333.28-39.95 -1.18%
NASDAQ9,548.60-202.36 -2.08%

UBS Downgrades BioNTech to Neutral, Raises Price Target to $35

UBS downgrades BioNTech (NASDAQ:BNTX) from Buy to Neutral and raises the price target from $21 to $35.

Benzinga · 01/22/2020 13:28

UBS downgrades BioNTech (NASDAQ:BNTX) from Buy to Neutral and raises the price target from $21 to $35.